基本信息
浏览量:32
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
个人简介
Dr Montse Sanchez-Cespedes graduated in Biology and obtained her PhD in Genetics and Molecular Biology from the Universidad de Barcelona in Spain. From 1997 to 2001 she was a Postdoctoral Fellow at The Johns Hopkins University School of Medicine, Baltimore-USA. Dr Sanchez-Cespedes focused on the identification of novel genetic and molecular alterations in lung cancer. During this period, she discovered that LKB1 was genetically inactivated in lung adenocarcinomas. Today this is a well-established tumor suppressor gene involved in lung cancer development. After that, she was the group leader first, at the Spanish National Cancer Centre (CNIO) in Madrid, Spain (until 2008) and later at the Bellvitge Biomedical Research Institute-IDIBELL in Barcelona, Spain (until 2019). Now, she leads the Cancer Genetics Group at the Josep Carreras Research Institute in Badalona, Barcelona, Spain.
Over all these years, her group has made important contributions to the dissection and identification of gene alterations and expression profiles in lung cancer. These include, among others, the discovery of genetic inactivation of SMARCA4 (also BRG1), coding the ATPase of the SWI/SNF chromatin remodelling complex, and of MAX, binding partner of the MYC oncoprotein, in small cell lung cancer.
The laboratory of Dr Sanchez-Cespedes laboratory is devoted to the genetic and molecular study of the mechanisms that drive cancer development. The group uses the latest high throughput sequencing technologies to create profiles and catalogues of the recurrently altered genes in cancer. Further, we are actively investigating the mechanistics that underlie the inactivation of SMARCA4 and the des-regulation of the MYC/MAX network contribution to cancer development. Finally, through collaborations with clinicians and pathologists within our network of nearby hospitals, we pursue the identification and characterization of genetic and molecular features that predict response to novel therapeutics. Ultimately, our purpose is to implement the clinical management of cancer patients and to design novel therapeutic strategies.
研究兴趣
论文共 120 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
LUNG CANCER (2024): 107502-107502
Octavio A. Romero,Manuel Torres-Diz,Eva Pros,Suvi Savola,Antonio Gomez,Sebastian Moran, Carmen Saez,Reika Iwakawa, Alberto Villanueva,Luis M. Montuenga,Takashi Kohno,Jun Yokota,
crossref(2023)
Ester Bonastre,Sara Verdura, Ilse Zondervan,Federica Facchinetti, Sylvie Lantuejoul,Maria Dolores Chiara, Juan Pablo Rodrigo,Julian Carretero,Enric Condom, Agustin Vidal,David Sidransky, Alberto Villanueva,
crossref(2023)
crossref(2023)
crossref(2023)
Juan J. Alburquerque-Bejar, Pablo Navajas-Chocarro,Maria Saigi, Ana Ferrero-Andres, Juan M. Morillas,Andrea Vilarrubi,Antonio Gomez,José L. Mate,Ana M. Munoz-Marmol,Octavio A. Romero,Pedro Blecua,Veronica Davalos,
Cell Reports Medicineno. 4 (2023): 101006-101006
Ester Bonastre,Sara Verdura, Ilse Zondervan,Federica Facchinetti, Sylvie Lantuejoul,Maria Dolores Chiara, Juan Pablo Rodrigo,Julian Carretero,Enric Condom, Agustin Vidal,David Sidransky, Alberto Villanueva,
crossref(2023)
crossref(2023)
Ester Bonastre,Sara Verdura, Ilse Zondervan,Federica Facchinetti, Sylvie Lantuéjoul, María Dolores Chiara, Juan P. Rodrigo,Julián Carretero,Enric Condom,August Vidal,David Sidransky, Alberto Villanueva,
openalex(2023)
Cell reports. Medicineno. 4 (2023): 101006-101006
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn